Najat Aourz

02 477 4429

Despite recent advances and a wide number of new antiseizure drugs (ASDs) developed over the past decades, approximately 30 % of all epilepsy patients suffers from refractory seizures with significant associated morbidity and economic impact worldwide. My research work mainly focuses on identifying new compounds with anticonvulsant activity and with modes of action, distinct from the currently available ASDs. The latter largely duplicate the actions of existing drugs and offering little or no therapeutic gain in the treatment of refractory seizures. The main targets of interest include mainly small molecules, such as neuropeptide analogues and protein kinases.

Researchgate Najat Aourz


Research themes

Target-driven drug discovery approaches for refractory epilepsy